Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
39.5 HKD | -4.59% | -3.42% | -7.60% |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Sales forecast by analysts have been recently revised upwards.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is not the most generous with respect to shareholders' compensation.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-7.60% | 8.62B | B- | ||
-2.35% | 89.08B | A- | ||
+3.55% | 40.9B | A- | ||
-13.38% | 32.25B | B- | ||
+54.06% | 25.14B | A | ||
-15.91% | 15.39B | C | ||
-8.52% | 11.91B | B- | ||
-41.29% | 11.89B | B | ||
-12.82% | 11.64B | D+ | ||
+7.42% | 9.03B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 1801 Stock
- Ratings Innovent Biologics, Inc.